Response to Dal-Re and Holm’s ethical concern regarding the UK PANORAMIC COVID-19 trial by the PANORAMIC Investigators was written by Butler, Christopher C.;the PANORAMIC Trial Investigators. And the article was included in British Journal of Clinical Pharmacology in 2022.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate The following contents are mentioned in the article:
In this article the author discusses about response to Dal-Re and Holm’s ethical concern regarding UK PANORAMIC COVID-19 trial by PANORAMIC investigators. All participants are able to receive standard best available care, regardless of whether they are receive an antiviral in PANORAMIC or not. If randomized to an anti-viral arm in PANORAMIC, participants who are eligible for CMDU treatment can also be given a neutralizing monoclonal antibody (nMAB) or an antiviral drug outside of PANORAMIC. This is all at the discretion of the clinician in charge at the CMDU. Similarly, if randomized to Usual Care in PANORAMIC, participants can still receive an nMAB or an antiviral agent from a CMDU. The PANORAMIC Trial Website states that some may be eligible to receive antiviral treatment outside of the PANORAMIC Trial and that their clin. care remains under the direction of the NHS. The CDMUs were established to provide access to acute COVID treatments for the highest risk patients, a much smaller eligible population than all people over 50 or over 18 with a COVID risk factor eligible for PANORAMIC. The care pathways are complementary. Further, highest risk patients have been contacted with advice (and a PCR test kit) how to access a CDMU in the event they become infected and CDMUs are also contacting eligible people at highest risk if they test pos. Molnupiravir has conditional marketing approval in the UK, recognizing that clin. data for full authorization are not yet available. PANORAMIC is a key contribution to generate these data. For example, participants in the pivotal phase 3 trial (MOVe-OUT) were unvaccinated, exposed to different variants of SARs-CoV-2 from those in current circulation, and largely recruited in healthcare systems different from the UK. It is important to evaluate whether the treatment effect on which the conditional approval is based applies in a clin. relevant population in the UK. PANORAMIC thus represents a pragmatic means to assess molnupiravir and other potential treatments without denying participants access to treatments available through other approved routes. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF), or oxolane, is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. Tetrahydrofuran reaction with hydrogen sulfide: In the presence of a solid acid catalyst, tetrahydrofuran reacts with hydrogen sulfide to give tetrahydrothiophene.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem